Urinary Leukotriene E4 As a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis

Overview

Journal Curr Allergy Asthma Rep

Specialties Allergy & Immunology
Pulmonary Medicine

Date 2022 Nov 14

PMID 36374376

Authors

Malcolm Marquette

Bhavesh V Tailor

Philip C Calder

Peter J Curtis

Yoon Loke

Andrew M Wilson

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Non-steroidal exacerbated respiratory disease (N-ERD) currently requires aspirin challenge testing for diagnosis. Urinary leukotriene E4 (uLTE) has been extensively investigated as potential biomarker in N-ERD. We aimed to assess the usefulness of uLTE as a biomarker in the diagnosis of N-ERD.

Recent Findings: N-ERD, formerly known as aspirin-intolerant asthma (AIA), is characterised by increased leukotriene production. uLTE indicates cysteinyl leukotriene production, and a potential biomarker in N-ERD. Although several studies and have examined the relationship between uLTE and N-ERD, the usefulness of uLTE as a biomarker in a clinical setting remains unclear.

Findings: Our literature search identified 38 unique eligible studies, 35 were included in the meta-analysis. Meta-analysis was performed (i.e. pooled standardised mean difference (SMD) with 95% confidence intervals (95% CI)) and risk of bias assessed (implementing Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy (Cochrane DTA)). Data from 3376 subjects was analysed (1354 N-ERD, 1420 ATA, and 602 HC). uLTE was higher in N-ERD vs ATA (n = 35, SMD 0.80; 95% CI 0.72-0.89). uLTE4 increased following aspirin challenge in N-ERD (n = 12, SMD 0.56; 95% CI 0.26-0.85) but not ATA (n = 8, SMD 0.12; CI - 0.08-0.33). This systematic review and meta-analysis showed that uLTE is higher in N-ERD than ATA or HC. Likewise, people with N-ERD have greater increases in uLTE following aspirin challenge. However, due to the varied uLTE measurement and result reporting practice, clinical utility of these findings is limited. Future studies should be standardised to increase clinical significance and interpretability of the results.

Citing Articles

[Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs （2024, Chengdu）].

Meng J, Ye J, Zhang L, Xu Y, Liu W, Yang Y Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(6):453-462.

PMID: 38858107 PMC: 11480570. DOI: 10.13201/j.issn.2096-7993.2024.06.001.

The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS).

AlRuwaili R, Al-Kuraishy H, Alruwaili M, Khalifa A, Alexiou A, Papadakis M Mol Cell Biochem. 2023; 479(5):1267-1278.

PMID: 37395897 PMC: 11116240. DOI: 10.1007/s11010-023-04793-1.

References

Swierczynska-Krepa M, Sanak M, Bochenek G, Strek P, Cmiel A, Gielicz A . Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014; 134(4):883-90. DOI: 10.1016/j.jaci.2014.02.041. View

Cahill K, Cui J, Kothari P, Murphy K, Raby B, Singer J . Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. Am J Respir Crit Care Med. 2019; 200(6):704-711. PMC: 6775876. DOI: 10.1164/rccm.201809-1755OC. View

Mita H, Endoh S, Kudoh M, Kawagishi Y, Kobayashi M, Taniguchi M . Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy. 2001; 56(11):1061-7. DOI: 10.1111/j.1398-9995.2001.00913.x. View

Christie P, Tagari P, Ford-Hutchinson A, Charlesson S, Chee P, Arm J . Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991; 143(5 Pt 1):1025-9. DOI: 10.1164/ajrccm/143.5_Pt_1.1025. View

Bochenek G, Nizankowska E, Gielicz A, Swierczynska M, Szczeklik A . Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax. 2004; 59(6):459-64. PMC: 1747024. DOI: 10.1136/thx.2003.013573. View

Rajan J, Wineinger N, Stevenson D, White A . Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2014; 135(3):676-81.e1. DOI: 10.1016/j.jaci.2014.08.020. View

Montuschi P, Santini G, Valente S, Mondino C, Macagno F, Cattani P . Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 964:12-25. DOI: 10.1016/j.jchromb.2014.02.059. View

Yamaguchi T, Ishii T, Yamamoto K, Higashi N, Taniguchi M, Okamoto M . Differences in urinary leukotriene E4 levels and distribution of eosinophils between chronic rhinosinusitis patients with aspirin-intolerant and -tolerant asthma. Auris Nasus Larynx. 2015; 43(3):304-8. DOI: 10.1016/j.anl.2015.09.016. View

Kawagishi Y, Mita H, Taniguchi M, Maruyama M, Oosaki R, Higashi N . Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol. 2002; 109(6):936-42. DOI: 10.1067/mai.2002.124466. View

10.

Micheletto C, Tognella S, Visconti M, Trevisan F, Dal Negro R . Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics. Respir Med. 2006; 100(12):2144-50. DOI: 10.1016/j.rmed.2006.03.017. View

11.

Mastalerz L, Sanak M, Szczeklik A . Serum interleukin-5 in aspirin-induced asthma. Clin Exp Allergy. 2001; 31(7):1036-40. DOI: 10.1046/j.1365-2222.2001.01105.x. View

12.

Daffern P, Muilenburg D, Hugli T, Stevenson D . Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol. 1999; 104(3 Pt 1):559-64. DOI: 10.1016/s0091-6749(99)70324-6. View

13.

Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A . Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax. 2007; 63(1):27-34. DOI: 10.1136/thx.2007.080903. View

14.

Higashi N, Mita H, Ono E, Fukutomi Y, Yamaguchi H, Kajiwara K . Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol. 2010; 125(5):1084-1091.e6. DOI: 10.1016/j.jaci.2009.12.977. View

15.

Wangberg H, White A . Aspirin-exacerbated respiratory disease. Curr Opin Immunol. 2020; 66:9-13. DOI: 10.1016/j.coi.2020.02.006. View

16.

Jenkins C, Costello J, Hodge L . Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004; 328(7437):434. PMC: 344260. DOI: 10.1136/bmj.328.7437.434. View

17.

Obase Y, Shimoda T, Tomari S, Mitsuta K, Fukushima C, Kawano T . Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients. Ann Allergy Asthma Immunol. 2001; 87(1):74-9. DOI: 10.1016/s1081-1206(10)62328-9. View

18.

Laidlaw T, Kidder M, Bhattacharyya N, Xing W, Shen S, Milne G . Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012; 119(16):3790-8. PMC: 3335383. DOI: 10.1182/blood-2011-10-384826. View

19.

Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K . A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy. 2002; 32(10):1484-90. DOI: 10.1046/j.1365-2745.2002.01507.x. View

20.

Higashi N, Taniguchi M, Mita H, Ishii T, Akiyama K . Nasal blockage and urinary leukotriene E4 concentration in patients with seasonal allergic rhinitis. Allergy. 2003; 58(6):476-80. DOI: 10.1034/j.1398-9995.2003.00159.x. View